Management ChangeAug 10, 2026, 04:43 PM
Annexon Appoints Mark S. Blumenkranz to Board; Muneer Satter Resigns
AI Summary
Annexon, Inc. announced the appointment of Mark S. Blumenkranz, M.D., M.S.S., to its Board of Directors, effective August 10, 2026. Dr. Blumenkranz, a renowned retinal surgeon and biotechnology entrepreneur, will also join the Audit and Science and Technology committees. Concurrently, Muneer Satter resigned from the Board and its committees after over 11 years of distinguished service, with his departure not resulting from any disagreement with the company.
Key Highlights
- Mark S. Blumenkranz, M.D., M.S.S., was appointed to Annexon's Board of Directors, effective August 10, 2026.
- Dr. Blumenkranz will serve as a Class II director with a term expiring at the 2028 annual meeting.
- He was also appointed as a member of the Audit Committee and Science and Technology Committee.
- Muneer Satter resigned from the Board and its committees after more than eleven years of service.
- Dr. Blumenkranz will receive a $40,000 annual retainer for his board service.
- He received an initial stock option grant to purchase 175,000 shares of common stock.
- He will also receive annual stock option grants to purchase 65,000 shares of common stock.
Price Impact
More from ANNX